Breakthrough in research and development of genetic engineering vaccine for HFMD of Chinese Academy of Sciences

Liu Qingwei, Ph.D candidate of vaccine science and antiviral strategy research group of Shanghai Pasteur Institute of Chinese Academy of Sciences, developed a genetically engineered vaccine against Coxsackie virus a16 (CA16) under the guidance of researcher Huang Zhong This is the first attempt to develop CA16 genetic engineering vaccine in the world The results show that the vaccine strategy based on VLP (virus like particles) is feasible, which lays a foundation for further development of bivalent HFMD vaccine against EV71 (enterovirus 71) and CA16 Relevant research papers have been published online in the international famous journal vaccine Hand, foot and mouth disease is a common infectious disease in children EV71 and CA16 are the main pathogens Both of them can cause neurological symptoms and even death in children The proportion of the former is higher than that of the latter; a small number of patients even have two kinds of viruses at the same time Statistics show that from January 2008 to August 2012, there were more than 6.67 million HFMD cases and 2362 deaths in mainland China At present, the inactivated vaccine for EV71 has entered the clinical trial stage, while the vaccine development for CA16 has just begun Under the guidance of Huang Zhong, Liu Qingwei and others carried out the research of genetically engineered vaccine for CA16 Using baculovirus expression system of insect to express P1 and 3CD protein of CA16, researchers obtained virus like particles of CA16, which have similar structure with virus, no viral nucleic acid and no infectivity In vitro neutralization test showed that VLP immune serum could effectively inhibit the infection of homologous and heterologous CA16 virus Further animal experiments showed that anti VLP serum had a good protective effect on the lethal dose of homologous or heterologous CA16 virus.